NEWS DETAIL

Telix Receives €545,000 Belgian Research Grant for Prostate Cancer Imaging Agent in Europe

Melbourne (Australia) and Liège (Belgium) – 19th November 2020. Advanced Nuclear Medicine Ingredients S.A. (‘ANMI’), a wholly owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’), announces today that it has received a €545,000 (~AU$893,000) payment from the Walloon regional government in Belgium. This payment represents part of a €1,320,000 innovation grant awarded to ANMI to support the preclinical R&D and early clinical development of the Company’s prostate cancer imaging product TLX591-CDx ( 68Ga-PSMA-11).

Under the terms of the grant, in the event that the innovation grant funding results in developments or intellectual property that are subsequently used in a commercialised product, a fixed portion of the amount awarded (30%) must be repaid over a period of 10 years.

Ludovic Wouters, Telix Pharmaceuticals EU President and ANMI Co-Founder stated, “The Walloon region has become a favourable environment for life science innovation and this continuing support validates our decision to expand Telix's footprint in Belgium with the recent acquisition of the radiopharmaceutical manufacturing facility in Seneffe. We appreciate the region's commitment to the biotechnology sector, a primary factor in Telix's choice of Wallonia as our European headquarters.”

About TLX591-CDx

Telix’s prostate cancer imaging product TLX591-CDx ( 68Ga-PSMA-11) is the Company’s most developmentally advanced product and is presently used under investigational (IND), clinical trial and special access use in the United States and Europe. The ‘cold kit’ format of TLX591-CDx enables rapid radiolabelling at room temperature with high radiochemical purity and production consistency, ideally suited for the radiopharmacy setting.1

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

1 TLX591-CDx has not received a marketing authorisation in any jurisdiction.

Telix Corporate Contact
Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: [email protected]

Telix Investor Relations
Dr David N. Cade
Telix Pharmaceuticals Limited
CBO and Head of Investor Relations
Email: [email protected]

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.